Diagnosis of atypical carcinoid can be made on biopsies > 4 mm
Atypical carcinoid
Biopsy size
Endobronchial therapy Ki-67
Typical carcinoid
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
23
08
2021
accepted:
13
01
2022
revised:
15
12
2021
pubmed:
29
1
2022
medline:
12
4
2022
entrez:
28
1
2022
Statut:
ppublish
Résumé
In the 2021 WHO thoracic tumors, gradation of lung carcinoids in biopsies is discouraged. We hypothesized that atypical carcinoid (AC) could be reliably diagnosed in larger preoperative biopsies. Biopsy-resection paired specimens of carcinoid patients were included, and definitive diagnosis was based on the resection specimen according to the WHO 2021 classification. A total of 64 biopsy-resection pairs (26 typical carcinoid (TC) (41%) and 38 AC (59%)) were analyzed. In 35 patients (55%), tumor classification between the biopsy and resection specimen was concordant (26 TC, 9 AC). The discordance in the remaining 29 biopsies (45%, 29 TC, 0 AC) was caused by misclassification of AC as TC. In biopsies measuring < 4 mm
Identifiants
pubmed: 35089404
doi: 10.1007/s00428-022-03279-7
pii: 10.1007/s00428-022-03279-7
pmc: PMC8989857
doi:
Substances chimiques
Ki-67 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
587-593Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
WHO Classification of Tumours, 5th Edition, Volume 5, 2021
Marx A, Chan J, Coindre J, Detterbeck F et al (2015) The 2015 WHO Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol 10(10):1383–1395
Travis W (2014) Pathology and diagnosis of neuroendocrine tumors. Thorac Surg Clin 24(3):257-66
Richards-Taylor S, Ewings SM, Jaynes E, Tilley C, Ellis SG, Armstrong T et al (2016) The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis. J Clin Pathol 69(7):612–618
doi: 10.1136/jclinpath-2015-203340
Warth A, Fink L, Fisseler-Eckhoff A, Jonigk D, Keller M, Ott G et al (2013) Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids. Virchows Arch 462(5):507–513
doi: 10.1007/s00428-013-1408-2
Pelosi G, Rindi G, Travis WD, Papotti M (2014) Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol 9(3):273–284
doi: 10.1097/JTO.0000000000000092
Reuling E, Dickhoff C, Plaisier PW, Coupe VMH, Mazairac AHA, Lely RJ et al (2018) Endobronchial treatment for bronchial carcinoid: patient selection and predictors of outcome. Respiration 95(4):220-227
Marchiò C, Gatti G, Massa F, Bertero L, Filosso P, Pelosi G et al (2017) Distinctive pathological and clinical features of lung carcinoids with high proliferation index. Virchows Arch 471(6):713–720
doi: 10.1007/s00428-017-2177-0
Oka N, Kasajima A, Konukiewitz B, Sakurada A, Okada Y, Kameya T et al (2020) Classification and prognostic stratification of bronchopulmonary neuroendocrine neoplasms. Neuroendocrinology 110(5):393–403
doi: 10.1159/000502776
Swarts DR, Rudelius M, Claessen SM, Cleutjens JP, Seidl S, Volante M et al (2017) Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids. Histopathology 70(3):412–422
doi: 10.1111/his.13096
Baak JPA (1991) Manual of quantitative pathology in cancer diagnosis and prognosis. Springer
Brokx HA, Paul MA, Postmus PE, Sutedja TG (2015) Long-term follow-up after first-line bronchoscopic therapy in patients with bronchial carcinoids. Thorax 70(5):468–472
doi: 10.1136/thoraxjnl-2014-206753
Fruchter O, Fuks L, Amital A, Fox BD, Abdel Rahman N, Kramer MR (2009) Long-term follow-up of flexible bronchoscopic treatment for bronchial carcinoids with curative intent. Diagn Ther Endosc
Neyman K, Sundset A, Naalsund A, Espinoza A, Solberg S, Kongerud J et al (2012) Endoscopic treatment of bronchial carcinoids in comparison to surgical resection: a retrospective study. J Bronchol Interv Pulmonol 19(1):29–34
doi: 10.1097/LBR.0b013e3182446b52
Reuling EMBP, Dickhoff C, Plaisier PW, Bonjer HJ, Daniels JMA (2019) Endobronchial and surgical treatment of pulmonary carcinoid tumors; a systematic literature review. Lung Cancer 134:85-95
Neuberger M, Hapfelmeier A, Schmidt M, Gesierich W, Reichenberger F, Morresi-Hauf A, et al (2015) Carcinoid tumours of the lung and the ‘PEPPS’ approach: evaluation of preoperative bronchoscopic tumour debulking as preparation for subsequent parenchyma-sparing surgery. BMJ Open Respir Res 2(1):e000090
Rizzardi G, Marulli G, Bortolotti L, Calabrese F, Sartori F, Rea F (2008) Sleeve resections and bronchoplastic procedures in typical central carcinoid tumours. Thorac Cardiovasc Surg 56(1):42–45
doi: 10.1055/s-2007-965741
Moonen L, Derks JL, Hermans BCM, Bunnik IM, Hillen LM, Jan van Suylen R et al (2020) Pre-operative biopsy diagnosis in pulmonary carcinoids, a shot in the dark. J Thorac Oncol 16(4):610-618
Boland JM, Kroneman TN, Jenkins SM, Terra S, Xie H, Molina J et al (2020) Ki-67 labeling index in pulmonary carcinoid tumors: comparison between small biopsy and resection using tumor tracing and hot spot methods. Arch Pathol Lab Med, Online ahead of print
Derks JL, Dingemans AC, van Suylen RJ, den Bakker MA, Damhuis RAM, van den Broek EC et al (2019) Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens? Histopathology 74(4):555–566
doi: 10.1111/his.13800
Bigras G, Mairs S, Swanson PE, Morel D, Lai R, Izevbaye I (2018) Small biopsies misclassify up to 35% of PD-L1 assessments in advanced lung non-small cell lung carcinomas. Appl Immunohistochem Mol Morphol 26(10):701–708
doi: 10.1097/PAI.0000000000000698
Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, et al (2020) Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. Mod Pathol 33(5):792–801